The following is a summary of "Real-world comparison of T2-biologics effectiveness in severe allergic asthma with nasal ...

Nasal polyps are thought to affect around 5% of people ... "I was going around the house sniffing everything – coffee, ...

Nasal polyps are thought to affect around 5% of the ... He said: “I was going around the house sniffing everything – coffee, perfume, the flowers in the garden. It was fantastic.

Tezepelumab reduced the size of nasal polyps and the severity of nasal congestion in patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps, in a placebo-controlled study.

Recent studies examine the burden of CRSwNP, looking at quality of life in patients and caregivers and assessing how CRSwNP ...

In the study, "Efficacy and Safety of Twice-Yearly Depemokimab in Chronic Rhinosinusitis with Nasal Polyps (ANCHOR-1 and ANCHOR-2)," published in The Lancet, researchers conducted randomized ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN DIEGO -- Tezepelumab (Tezspire) reduced nasal polyps and symptoms in severe chronic rhinosinusitis while also ...

Full results from the positive phase III WAYPOINT trial showed AstraZeneca and Amgen’s Tezspire (tezepelumab) significantly reduced nasal polyp severity, the need for subsequent surgery, and systemic ...